STOCK COMMENTS / EPS CHANGESAlexion Pharmaceuticals ( ALXN) numbers raised at Oppenheimer. Shares of ALXN now seen reaching $134, Oppenheimer said. Estimates also raised on headroom in the orphan disease franchise. Outperform rating. Endo ( ENDP) numbers cut at UBS. Shares of ENDP now seen reaching $45, UBS said. Estimates also lowered following investor day. Buy rating. Facebook ( FB) estimates, target reduced at JP Morgan. Shares of FB now seen reaching $28, according to JP Morgan. Estimates also cut, given the company's exposure to ZNGA. Overweight rating. Gap ( GPS) estimates, target increased at Piper. GPS estimates were raised through 2014, Piper Jaffray said. Company is carrying sales momentum into the Fall season. Overweight rating and new $42 price target. Informatica ( INFA) numbers cut at JMP. INFA estimates were reduced through 2013, JMP Securities said. Company cut guidance for a second straight quarter. Outperform rating and new $38 price target. Impax Labs ( IPXL) numbers boosted at BofA/Merrill. Shares of IPXL now seen reaching $25, according to Bank of America/Merrill Lynch said. Estimates also upped, as the company is seeing higher generic sales. Underperform rating. Marriott ( MAR) estimates, target raised at Nomura. Shares of MAR now seen reaching $48, according to Nomura. Estimates also increased, given higher expected RevPAR growth. Buy rating. >To submit a news tip, email: firstname.lastname@example.org.
Twitter and become a fan on Facebook.